|Lotus Pharmaceuticals Inc -- USA Stock|| |
USD 0.007 0.003 30%
VP of Corporate Devel.
Dr. Xing Shen, Ph.D., is Vice President Corporationrationrate Development of Lotus Pharmaceuticals, Inc. He was with the Company since July 2009. From July 2006 through May 2009, Mr. Shen was an associate equity analyst for RBC Capital Markets, where he cocovered approximately 30 companies in the biotech industry. Mr. Shen received a Masters of Business Administration in 2006 and a Doctorate in Molecular Cancer Biology in 2000 from Duke University. Mr. Shen received a MS in plant molecular biology from Peking University in 1995 and a BS in Virology from Wuhan University in 1992
Age: 39 VP Since 2010 CFA
86 10 6389 9868 http://www.lotuspharma.com
Shen has received Series 7, 63, 86 and 87 licenses from Finra and is a Chartered Financial Analyst level one candidate.
The company has return on total asset (ROA)
of 4.56 %
which means that it generated profit of $4.56 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE)
of 1.82 %
meaning that it created $1.82 on every $100 dollars invested by stockholders.
The company currently holds 6.18 M in liabilities with Debt to Equity (D/E) ratio of 6.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Lotus Pharmaceuticals Inc has Current Ratio of 0.52 indicating that it has a negative working capital and may not be able to pay financial obligations when they are due.
Lotus Pharmaceuticals, Inc. develops, manufactures, and sells pharmaceuticals in the People?s Republic of China. Lotus Pharmaceuticals Inc (LTUS) is traded on OTC Market in USA. It is located in Lotus Pharmaceuticals, Inc.Beijing, and employs 233 people.